Syndax completes enrollment in AUGMENT-101 trial

Syndax Pharmaceuticals announced completion of enrollment in the AUGMENT-101 pivotal trial cohort of patients with relapsed/refractory mutant nucleophosmin acute myeloid leukemia. Topline data is expected in the fourth quarter of 2024 and could support a supplemental New Drug Application filing for revumenib in R/R mNPM1 AML in the first half of 2025. “We are thrilled to announce that we are one step closer to potentially expanding the therapeutic reach of revumenib in genetically defined acute leukemias,” said Neil Gallagher, M.D., Ph.D., President, Head of Research and Development at Syndax. “We look forward to reporting topline data for this pivotal cohort in the fourth quarter of this year, which will follow closely behind a potential first approval of KMT2A acute leukemia in the third quarter.”